SEC Tracker
Get the app
PMI · XBRL financial data

Picard Medical financial statements, every quarter

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (PMI's year ends in late December)

In thousands of dollarsJun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026†Jun 30, 2026
Revenue2,131————
Revenue from contracts with customers2,1311,1871,009*1,1502,954
Cost of revenue2,2581,317598*8752,338
Gross profit(127)(130)411*275616
Research and development743951547*1,8951,374
Selling, general and administrative2,6512,4062,867*2,8913,871
Total operating expenses3,3943,3573,414*4,7865,245
Operating income (loss)(3,521)(3,487)(3,003)*(4,511)(4,629)
Interest expense2,427————
Other income (expense)0———13
Income tax expense (benefit)004*07
Net income (loss)(6,724)(10,426)(4,291)*(7,616)(5,660)
Earnings per share, basic USD per share(42.39)(0.19)—(0.10)(3.05)
Weighted average shares, basic thousands of shares17754,452—74,4381,856
  • † Share count changed about 1/39 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (PMI's year ends in late December)

In thousands of dollarsJun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026†Jun 30, 2026
Cash and cash equivalents4102,8137,45112138
Accounts receivable1,300————
Inventory6,9966,5527,3037,4455,970
Prepaid and other current assets—1,0601,2151,347970
Total current assets9,64311,58820,7269,5097,592
Property and equipment, net188169183184162
Right-of-use asset550474363284203
Goodwill615615615615615
Total assets11,70313,52122,54811,2209,167
Accounts payable6,3703,1202,0792,7113,323
Accrued liabilities1,371————
Total current liabilities45,6365,37318,69512,6597,451
Lease liability, non-current2341363400
Total liabilities45,9315,55318,75912,6687,451
Accumulated deficit(62,126)(72,552)(76,843)(84,459)(90,119)
Total stockholders' equity(54,493)7,9683,789(1,448)1,716
Total liabilities and equity11,70313,52122,54811,2209,167
Common shares outstanding (cover page) thousands of shares73,70173,70175,17992,3502,339
  • † Share count changed about 1/39 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (PMI's year ends in late December)

In thousands of dollarsJun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026†Jun 30, 2026
Net income (loss)(6,724)(10,426)(4,291)*(7,616)(5,660)
Stock-based compensation183*204*226*1651,380*
Depreciation and amortization40*41*40*4645*
Net cash from operating activities(2,541)*(6,514)*(4,377)*(3,800)(1,352)*
Purchases of property and equipment0*——260*
Net cash from investing activities0*0*—(26)0*
Proceeds from issuing common stock985*13,724*0*00*
Proceeds from issuing equity——0*2,100—
Net cash from financing activities2,278*8,949*13,017*(7,522)1,246*
Net change in cash(278)*2,403*8,638*(11,330)(83)*
  • † Share count changed about 1/39 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Picard Medical382,954(1,352)*2.3M0.0 quarters 10-QJun 30, 2026
Neuronetics19,19741,568(1,008)*76.2M19.0 quarters 10-QJun 30, 2026
Lakeland Industries17,90150,139(404)*9.9M— 10-QJul 31, 2026
AVITA Medical9,13921,702(3,496)*30.9M3.2 quarters 10-QJun 30, 2026
InfuSystem Holdings96436,9336,777*19.9M— 10-QJun 30, 2026
KORU Medical Systems8,28812,045216*46.2M— 10-QJun 30, 2026
Anika Therapeutics38,41232,610(684)*13.4M56.2 quarters 10-QJun 30, 2026
Sanara MedTech15,42128,1372,038*9.2M— 10-QJun 30, 2026
Stereotaxis10,4917,670(3,675)*100.2M2.9 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.